Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07174310 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

A Phase 3 study of Parkinson's Disease, sponsored by Hoffmann-La Roche.

Recruiting
Registry status
Phase 3
Development phase
900
Enrollment target
20
Study locations

NCT07174310 is a Phase 3 study of Parkinson's Disease that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 900 participants, above the 637-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (41% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07174310, a Phase 3 study of Parkinson's Disease, is actively recruiting participants, sponsored by Hoffmann-La Roche.

RECRUITING
Registry status
Phase 3
Development phase
900 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

Conditions Studied

Parkinson's Disease

Interventions

  • DRUG Placebo
  • DRUG Prasinezumab

Study Locations (20)

Florida

  • JEM Research LLC - Atlantis
  • Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
  • K2 - Villages - Lady Lake
  • K2 Medical Research-Maitland - Maitland
  • Charter Research - Winter Park/Orlando - Orlando

California

  • Neurology Center of North Orange County - Fullerton
  • Keck School of Medicine of USC - Los Angeles
  • Profound Research LLC at The Neurology Center of Southern California - Pasadena
  • UCSF Weill Institute for Neurosciences - San Francisco

New York

  • Dent Neurological Institute - Amherst
  • Weill Cornell Medical College - New York

Colorado

  • Rocky Mountain Movement Disorders - Englewood

Connecticut

  • Institute for Neurodegenerative Disorders - New Haven

Hawaii

  • Hawaii Pacific Neuroscience - Honolulu

Michigan

  • Quest Research Institute - Farmington Hills

Nevada

  • Renown Health - Reno

Trial Details

FieldValue
Enrollment Target 900 participants
Start Date 2025-11-24
Est. Completion 2031-06-30
Phase Phase 3

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07174310

The ClinicalTrials.gov registry entry for NCT07174310 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 637-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (41% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07174310 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, New York.

Frequently Asked Questions

What is clinical trial NCT07174310 about?

NCT07174310 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease". The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

What is the current status of trial NCT07174310?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2025-11-24. Estimated completion is 2031-06-30.

What conditions does trial NCT07174310 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT07174310?

The interventions under investigation include: Placebo (DRUG), Prasinezumab (DRUG).

Who is sponsoring clinical trial NCT07174310?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07174310 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson's Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.